Study results support development of LRIG1 as novel anti-cancer therapeutic
- Study is first to report that LRIG1 suppresses prostate cancer development
- LRIG1-derived peptide now being developed as anti-cancer therapeutic
- LRIG1 expression levels in tumors could become prognostic biomarker
San Francisco, CA (UroToday.com) — A research team led by a scientist at Roswell Park Comprehensive Cancer Center has identified the molecule LRIG1 as an important endogenous tumor suppressor in prostate cancer. Writing in the journal Nature Communications, the team documents their findings from preclinical studies showing that overexpression of the LRIG1 protein inhibits prostate cancer development while reducing naturally occurring LRIG1 promotes prostate tumor development.